Close Menu

NEW YORK – AI precision medicine firm Tempus said on Tuesday that it has obtained the CE mark for its cancer genomic sequencing assay, xT, making the test available for clinical use in Europe and other countries that accept the designation.

According to the company, the xT assay is already used by thousands of oncologists in the US, and broadening availability to European clinicians is part of the firm's regulatory strategy.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The US Centers for Disease Control and Prevention has identified a small group of breakthrough COVID-19 cases, the Wall Street Journal reports.

The New York Times reports that the US Department of Defense is to use genetic genealogy approaches to identify the remains of unknown soldiers.

Vox and Nature discuss the importance of preparing for the next pandemic.

In Nature this week: comparison of five circulating tumor DNA assays, resequencing analysis of lettuce gives insight into its domestication, and more.